PhD Scientific Days 2023

Budapest, 22-23 June 2023

Clinical Medicine - Posters J

Retrospective study of primary localized cutaneous amyloidosis

Sára Pálla1, Eszter Tóth1, Enikő Kuroli1, Márta Medvecz1
1 Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest

Text of the abstract

Primary localized cutaneous amyloidosis (PLCA) is a chronic dermatologic condition where the deposition of amyloid proteins is located in the papillary dermis. Three subtypes of PLCA are differentiated, macular amyloidosis (MA), lichen amyloidosis (LA) and nodular amyloidosis (NA). Due its rarity in the Caucasian population, data on its epidemiology and therapeutic possibilities are limited.
The aim of the study was to share clinical data and our clinical experience in the therapeutic possibilities regarding this rare cutaneous disorder.
In this retrospective study, we collected data of all PLCA cases diagnosed at the Department of Dermatology, Venereology and Dermatooncology, Semmelweis University between January 1, 2004, and December 31, 2022. Distribution of symptoms, age, sex, comorbidities, skin phototype, disease duration, treatment modalities and response to therapy were assessed.
41 patients diagnosed with PLCA were included in the study. Mean age at diagnosis was 54.6±15.2 years. MA was diagnosed in 22 patients and LA in 18 patients. Mean age at disease onset was 53±16.1 years. Most frequently, topical medium- or high-potency corticosteroid was applied, however, their effect on the symptoms was variable. In other cases, topical capsaicin, calcineurin inhibitor, phototherapy or oral retinoid was prescribed.
In this study, we provided epidemiologic characteristics of PLCA in the Caucasian population. We examined the effects of different therapeutic options on a large patient population, however further randomized controlled trials would be necessary to improve therapeutic possibilities for PLCA patients.
This work was supported by grants from the Hungarian National Research, Development and Innovation Office – NKFIH grant [FK_131916, 2019], and EFOP- 3.6.3-VEKOP-16-2017-00009.